Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

E2F1 inhibition mediates cell death of metastatic melanoma.

Rouaud F, Hamouda-Tekaya N, Cerezo M, Abbe P, Zangari J, Hofman V, Ohanna M, Mograbi B, El-Hachem N, Benfodda Z, Lebeau A, Tulic MK, Hofman P, Bertolotto C, Passeron T, Annicotte JS, Ballotti R, Rocchi S.

Cell Death Dis. 2018 May 9;9(5):527. doi: 10.1038/s41419-018-0566-1.

2.

Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.

El-Hachem N, Habel N, Naiken T, Bzioueche H, Cheli Y, Beranger GE, Jaune E, Rouaud F, Nottet N, Reinier F, Gaudel C, Colosetti P, Bertolotto C, Ballotti R.

Cell Death Differ. 2018 Mar 7. doi: 10.1038/s41418-018-0090-y. [Epub ahead of print]

PMID:
29515254
3.

A Novel Role for CSRP1 in a Lebanese Family with Congenital Cardiac Defects.

Kamar A, Fahed AC, Shibbani K, El-Hachem N, Bou-Slaiman S, Arabi M, Kurban M, Seidman JG, Seidman CE, Haidar R, Baydoun E, Nemer G, Bitar F.

Front Genet. 2017 Dec 18;8:217. doi: 10.3389/fgene.2017.00217. eCollection 2017.

4.

Author Correction: Gene isoforms as expression-based biomarkers predictive of drug response in vitro.

Safikhani Z, Smirnov P, Thu KL, Silvester J, El-Hachem N, Quevedo R, Lupien M, Mak TW, Cescon D, Haibe-Kains B.

Nat Commun. 2018 Jan 9;9(1):166. doi: 10.1038/s41467-017-02136-5.

5.

Gene isoforms as expression-based biomarkers predictive of drug response in vitro.

Safikhani Z, Smirnov P, Thu KL, Silvester J, El-Hachem N, Quevedo R, Lupien M, Mak TW, Cescon D, Haibe-Kains B.

Nat Commun. 2017 Oct 24;8(1):1126. doi: 10.1038/s41467-017-01153-8. Erratum in: Nat Commun. 2018 Jan 9;9(1):166.

6.

Integrative cancer pharmacogenomics to establish drug mechanism of action: drug repurposing.

El-Hachem N, Ba-Alawi W, Smith I, Mer AS, Haibe-Kains B.

Pharmacogenomics. 2017 Nov;18(16):1469-1472. doi: 10.2217/pgs-2017-0132. Epub 2017 Oct 23. No abstract available.

7.

Tissue specificity of in vitro drug sensitivity.

Yao F, Madani Tonekaboni SA, Safikhani Z, Smirnov P, El-Hachem N, Freeman M, Manem VSK, Haibe-Kains B.

J Am Med Inform Assoc. 2018 Feb 1;25(2):158-166. doi: 10.1093/jamia/ocx062.

PMID:
29016819
8.

Revisiting inconsistency in large pharmacogenomic studies.

Safikhani Z, Smirnov P, Freeman M, El-Hachem N, She A, Rene Q, Goldenberg A, Birkbak NJ, Hatzis C, Shi L, Beck AH, Aerts HJWL, Quackenbush J, Haibe-Kains B.

Version 3. F1000Res. 2016 Sep 16 [revised 2017 Jan 1];5:2333. doi: 10.12688/f1000research.9611.3. eCollection 2016.

9.

Defining the biological basis of radiomic phenotypes in lung cancer.

Grossmann P, Stringfield O, El-Hachem N, Bui MM, Rios Velazquez E, Parmar C, Leijenaar RT, Haibe-Kains B, Lambin P, Gillies RJ, Aerts HJ.

Elife. 2017 Jul 21;6. pii: e23421. doi: 10.7554/eLife.23421.

10.

AutoDock and AutoDockTools for Protein-Ligand Docking: Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1(BACE1) as a Case Study.

El-Hachem N, Haibe-Kains B, Khalil A, Kobeissy FH, Nemer G.

Methods Mol Biol. 2017;1598:391-403. doi: 10.1007/978-1-4939-6952-4_20.

PMID:
28508374
11.

A HAND to TBX5 Explains the Link Between Thalidomide and Cardiac Diseases.

Khalil A, Tanos R, El-Hachem N, Kurban M, Bouvagnet P, Bitar F, Nemer G.

Sci Rep. 2017 May 3;7(1):1416. doi: 10.1038/s41598-017-01641-3.

12.

Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy.

El-Hachem N, Gendoo DMA, Ghoraie LS, Safikhani Z, Smirnov P, Chung C, Deng K, Fang A, Birkwood E, Ho C, Isserlin R, Bader GD, Goldenberg A, Haibe-Kains B.

Cancer Res. 2017 Jun 1;77(11):3057-3069. doi: 10.1158/0008-5472.CAN-17-0096. Epub 2017 Mar 17.

PMID:
28314784
13.

Safikhani et al. reply.

Safikhani Z, El-Hachem N, Smirnov P, Freeman M, Goldenberg A, Birkbak NJ, Beck AH, Aerts HJ, Quackenbush J, Haibe-Kains B.

Nature. 2016 Nov 30;540(7631):E2-E4. doi: 10.1038/nature19839. No abstract available.

PMID:
27905430
14.

Safikhani et al. reply.

Safikhani Z, El-Hachem N, Smirnov P, Freeman M, Goldenberg A, Birkbak NJ, Beck AH, Aerts HJ, Quackenbush J, Haibe-Kains B.

Nature. 2016 Nov 30;540(7631):E11-E12. doi: 10.1038/nature20581. No abstract available.

PMID:
27905423
15.

Safikhani et al. reply.

Safikhani Z, El-Hachem N, Smirnov P, Freeman M, Goldenberg A, Birkbak NJ, Beck AH, Aerts HJ, Quackenbush J, Haibe-Kains B.

Nature. 2016 Nov 30;540(7631):E6-E8. doi: 10.1038/nature20172. No abstract available.

PMID:
27905416
16.

Assessment of pharmacogenomic agreement.

Safikhani Z, El-Hachem N, Quevedo R, Smirnov P, Goldenberg A, Juul Birkbak N, Mason C, Hatzis C, Shi L, Aerts HJ, Quackenbush J, Haibe-Kains B.

F1000Res. 2016 May 9;5:825. doi: 10.12688/f1000research.8705.1. eCollection 2016.

17.

PharmacoGx: an R package for analysis of large pharmacogenomic datasets.

Smirnov P, Safikhani Z, El-Hachem N, Wang D, She A, Olsen C, Freeman M, Selby H, Gendoo DM, Grossmann P, Beck AH, Aerts HJ, Lupien M, Goldenberg A, Haibe-Kains B.

Bioinformatics. 2016 Apr 15;32(8):1244-6. doi: 10.1093/bioinformatics/btv723. Epub 2015 Dec 9.

PMID:
26656004
18.

Public data and open source tools for multi-assay genomic investigation of disease.

Kannan L, Ramos M, Re A, El-Hachem N, Safikhani Z, Gendoo DM, Davis S, Gomez-Cabrero D, Castelo R, Hansen KD, Carey VJ, Morgan M, Culhane AC, Haibe-Kains B, Waldron L.

Brief Bioinform. 2016 Jul;17(4):603-15. doi: 10.1093/bib/bbv080. Epub 2015 Oct 12. Review.

19.

Characterization of Conserved Toxicogenomic Responses in Chemically Exposed Hepatocytes across Species and Platforms.

El-Hachem N, Grossmann P, Blanchet-Cohen A, Bateman AR, Bouchard N, Archambault J, Aerts HJ, Haibe-Kains B.

Environ Health Perspect. 2016 Mar;124(3):313-20. doi: 10.1289/ehp.1409157. Epub 2015 Jul 14.

20.

Thiazole derivatives as inhibitors of cyclooxygenases in vitro and in vivo.

El-Achkar GA, Jouni M, Mrad MF, Hirz T, El Hachem N, Khalaf A, Hammoud S, Fayyad-Kazan H, Eid AA, Badran B, Merhi RA, Hachem A, Hamade E, Habib A.

Eur J Pharmacol. 2015 Mar 5;750:66-73. doi: 10.1016/j.ejphar.2015.01.008. Epub 2015 Jan 21.

PMID:
25617797
21.

Importance of collection in gene set enrichment analysis of drug response in cancer cell lines.

Bateman AR, El-Hachem N, Beck AH, Aerts HJ, Haibe-Kains B.

Sci Rep. 2014 Feb 13;4:4092. doi: 10.1038/srep04092.

22.

Inconsistency in large pharmacogenomic studies.

Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, Quackenbush J.

Nature. 2013 Dec 19;504(7480):389-93. doi: 10.1038/nature12831. Epub 2013 Nov 27.

23.

mRMRe: an R package for parallelized mRMR ensemble feature selection.

De Jay N, Papillon-Cavanagh S, Olsen C, El-Hachem N, Bontempi G, Haibe-Kains B.

Bioinformatics. 2013 Sep 15;29(18):2365-8. doi: 10.1093/bioinformatics/btt383. Epub 2013 Jul 3.

PMID:
23825369
24.

Regulation of de novo ceramide synthesis: the role of dihydroceramide desaturase and transcriptional factors NFATC and Hand2 in the hypoxic mouse heart.

Azzam R, Hariri F, El-Hachem N, Kamar A, Dbaibo G, Nemer G, Bitar F.

DNA Cell Biol. 2013 Jun;32(6):310-9. doi: 10.1089/dna.2013.1993. Epub 2013 May 14.

25.

New analogues of 13-hydroxyocatdecadienoic acid and 12-hydroxyeicosatetraenoic acid block human blood platelet aggregation and cyclooxygenase-1 activity.

Hirz T, Khalaf A, El-Hachem N, Mrad MF, Abdallah H, Créminon C, Grée R, Merhi RA, Habib A, Hachem A, Hamade E.

Chem Cent J. 2012 Dec 10;6(1):152. doi: 10.1186/1752-153X-6-152.

26.

Identification of new GATA4-small molecule inhibitors by structure-based virtual screening.

El-Hachem N, Nemer G.

Bioorg Med Chem. 2011 Mar 1;19(5):1734-42. doi: 10.1016/j.bmc.2011.01.022. Epub 2011 Jan 18.

PMID:
21310620

Supplemental Content

Loading ...
Support Center